Living Conditions After Non-Hodgkin's Lymphoma in France
NCT ID: NCT05583318
Last Updated: 2025-07-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
1570 participants
OBSERVATIONAL
2023-09-01
2023-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is also one of the first studies to look at epidemiological indicators of net survival after diagnosis of follicular lymphoma and diffuse large B-cell lymphoma, adjusted for clinical factors such as disease stage, therapeutic management, and comorbidities, apart from the standard adjustment factors of age, sex, and time of diagnosis in real life. In addition, the proportion of cured patients will be estimated.
For component 1, this will be the survival analysis on the initial data. For part 2, questionnaires will be sent out followed by a follow-up if necessary one month after the mailing. There is no physical interview nor any specific biological or imaging examination.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or Region
NCT04859920
Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)
NCT03104478
Application of Telemedicine to the Management of Aggressive Lymphomas
NCT03336138
Prospective Data Collection of Newly Diagnosed Hodgkin's Disease and Non-Hodgkin's Lymphoma Cases
NCT00538551
EBV-associated Diffuse Large B Cell Lymphoma
NCT03378947
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1: Patients diagnosed with non-Hodgkin's lymphoma
Diagnosis period 2010-2018, from the hematological malignancy registries of Côte-d'Or, Gironde, Basse-Normandie
Data collection
Data from hematological malignancy registries
Part 2: Patients diagnosed with live non-Hodgkin's lymphoma after vital status update
Update of vital status in December 2022
Questionnaires
9 questionnaires were sent out:
1. QLQ-C30 and SF-12 Quality of Life Questionnaire.
2. Oral quality of life questionnaire QLQ-OH15
3. Sexuality questionnaire SHQ-C22
4. Anxiety and depression questionnaire HADS,
5. Rosenberg Self-Esteem Questionnaire
6. RNLI Reintegration to Normal Life Questionnaire
7. Social Support Questionnaire SSQ6,
8. Socio-economic status questionnaire EPICES,
9. Complementary questionnaire collecting data on socio-professional status.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Data collection
Data from hematological malignancy registries
Questionnaires
9 questionnaires were sent out:
1. QLQ-C30 and SF-12 Quality of Life Questionnaire.
2. Oral quality of life questionnaire QLQ-OH15
3. Sexuality questionnaire SHQ-C22
4. Anxiety and depression questionnaire HADS,
5. Rosenberg Self-Esteem Questionnaire
6. RNLI Reintegration to Normal Life Questionnaire
7. Social Support Questionnaire SSQ6,
8. Socio-economic status questionnaire EPICES,
9. Complementary questionnaire collecting data on socio-professional status.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with a diagnosis of follicular lymphoma (9690/3, 9691/3, 9695/3, 9698/3, 9597/3)
* Patients with a diagnosis of diffuse large B-cell lymphoma (9678/3, 9679/3, 9680/3, 9684/3, 9688/3, 9712/3, 9735/3, 9737/3, 9738/3)
* For Part 2: Individuals alive at the date of vital status update
* Other forms of malignant hemopathies at diagnosis,
* Minors.
Exclusion Criteria
* Person under a legal protection measure (guardianship, tutorship)
* Pregnant, parturient or breastfeeding women
* Major incapable or unable to express his consent
* Person who did not return the questionnaires following the 1-month follow-up, or patient who expressed refusal to participate.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Dijon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Dijon Bourgogne
Dijon, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MAYNADIE 2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.